Thursday, August 23, 2012
Sunday, August 12, 2012
New article from Current Biology promoting use of psilocybin for depression
Neuroimaging: a scanner, colourfully.
Two recent studies report changes in human brain responses after exposure to psilocybin, the active ingredient of hallucinogenic mushrooms. Psilocybin increased sensory cortex responses during emotional recollection, but decreased resting-state blood flow in prefrontal cortex, with potential implications for treating depression. Roiser JP, Rees G. Curr Biol. 2012 Apr 10;22(7):R231-3. PMID: 22497939
Cited by (Google Scholar)
And here is a recent article that describes the use of Ayahuasca for depression:
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study.
Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in a bigger sample and to investigate its effects on regional cerebral blood flow. In an open-label trial conducted in an inpatient psychiatric unit, 17 patients with recurrent depression received an oral dose of ayahuasca (2.2 mL/kg) and were evaluated with the Hamilton Rating Scale for Depression, the Montgomery-Åsberg Depression Rating Scale, the Brief Psychiatric Rating Scale, the Young Mania Rating Scale, and the Clinician Administered Dissociative States Scale during acute ayahuasca effects and 1, 7, 14, and 21 days after drug intake. Blood perfusion was assessed eight hours after drug administration by means of single photon emission tomography. Ayahuasca administration was associated with increased psychoactivity (Clinician Administered Dissociative States Scale) and significant score decreases in depression-related scales (Hamilton Rating Scale for Depression, Montgomery-Åsberg Depression Rating Scale, Brief Psychiatric Rating Scale) from 80 minutes to day 21. Increased blood perfusion in the left nucleus accumbens, right insula and left subgenual area, brain regions implicated in the regulation of mood and emotions, were observed after ayahuasca intake. Ayahuasca was well tolerated. Vomiting was the only adverse effect recorded, being reported by 47% of the volunteers. Our results suggest that ayahuasca may have fast-acting and sustained antidepressive properties. These results should be replicated in randomized, double-blind, placebo-controlled trials.
Sanches RF, de Lima Osório F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L, de Araujo DB, Riba J, S Crippa JA, Hallak JE.
J Clin Psychopharmacol. 2015 Dec 8. [Epub ahead of print]
PMID: 26650973
Cited by (Google Scholar)
Two recent studies report changes in human brain responses after exposure to psilocybin, the active ingredient of hallucinogenic mushrooms. Psilocybin increased sensory cortex responses during emotional recollection, but decreased resting-state blood flow in prefrontal cortex, with potential implications for treating depression. Roiser JP, Rees G. Curr Biol. 2012 Apr 10;22(7):R231-3. PMID: 22497939
Cited by (Google Scholar)
And here is a recent article that describes the use of Ayahuasca for depression:
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study.
Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of ayahuasca in a bigger sample and to investigate its effects on regional cerebral blood flow. In an open-label trial conducted in an inpatient psychiatric unit, 17 patients with recurrent depression received an oral dose of ayahuasca (2.2 mL/kg) and were evaluated with the Hamilton Rating Scale for Depression, the Montgomery-Åsberg Depression Rating Scale, the Brief Psychiatric Rating Scale, the Young Mania Rating Scale, and the Clinician Administered Dissociative States Scale during acute ayahuasca effects and 1, 7, 14, and 21 days after drug intake. Blood perfusion was assessed eight hours after drug administration by means of single photon emission tomography. Ayahuasca administration was associated with increased psychoactivity (Clinician Administered Dissociative States Scale) and significant score decreases in depression-related scales (Hamilton Rating Scale for Depression, Montgomery-Åsberg Depression Rating Scale, Brief Psychiatric Rating Scale) from 80 minutes to day 21. Increased blood perfusion in the left nucleus accumbens, right insula and left subgenual area, brain regions implicated in the regulation of mood and emotions, were observed after ayahuasca intake. Ayahuasca was well tolerated. Vomiting was the only adverse effect recorded, being reported by 47% of the volunteers. Our results suggest that ayahuasca may have fast-acting and sustained antidepressive properties. These results should be replicated in randomized, double-blind, placebo-controlled trials.
Sanches RF, de Lima Osório F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L, de Araujo DB, Riba J, S Crippa JA, Hallak JE.
J Clin Psychopharmacol. 2015 Dec 8. [Epub ahead of print]
PMID: 26650973
Cited by (Google Scholar)
Wednesday, August 8, 2012
PTSD, Mindfulness and Yoga: Huffington 08/07/2012
Yoga: How We Serve Our Veterans
This is an interview with Felice Brenner, who had been working as a "headhunter" for 20 years to become a full-time yoga instructor. She teaches two classes a week at the Veterans Administration in Boston, Jamaica Plains campus. This year, Felice received the Outstanding Federal Volunteer award from the VA Boston Healthcare System for her service and commitment. Huffington Post
This is an interview with Felice Brenner, who had been working as a "headhunter" for 20 years to become a full-time yoga instructor. She teaches two classes a week at the Veterans Administration in Boston, Jamaica Plains campus. This year, Felice received the Outstanding Federal Volunteer award from the VA Boston Healthcare System for her service and commitment. Huffington Post
Monday, August 6, 2012
New Study on PTSD in the Journal Mindfulness
A Prospective Investigation of Mindfulness Skills and Changes in Emotion Regulation Among Military Veterans in Posttraumatic Stress Disorder Treatment
We prospectively investigated associations between mindfulness and changes in the use of expressive suppression and cognitive reappraisal occurring during a residential treatment program for posttraumatic stress disorder (PTSD). The sample consisted of 50 male veterans who were assessed with the Kentucky Inventory of Mindfulness Skills at treatment intake, and the Emotion Regulation Questionnaire (ERQ) and PTSD Checklist—Military Version at treatment intake and discharge. Hierarchical multiple regressions indicated that greater nonjudgmental acceptance at intake predicted greater reductions in expressive suppression (p < .05) and less improvement in cognitive reappraisal (p < .05) between treatment intake and discharge. Additionally, greater ability to observe thoughts, emotions, and sensations at intake was associated with less improvement in cognitive reappraisal between treatment intake and discharge (p < .05). Findings remained significant after statistically adjusting for treatment-related changes in PTSD symptoms.
2012, DOI: 10.1007/s12671-012-0131-4
Thursday, August 2, 2012
Lancet: a new editorial on psychedelic research
Shaping the renaissance of psychedelic research
Psychedelic drugs have a rich and vibrant history as clinical aids for psychiatry. For two decades after the discovery of lysergide (LSD) in the 1940s, psychedelics were extensively studied and clinical progress was good. But research collapsed rapidly in 1966 when LSD was made illegal, and there was a subsequent hiatus of psychedelic research. After 40 years, this pause is now coming to an end, with many new studies and a refreshing approach to the research of psychedelic drugs. Lancet. 2012 Jul 21;380(9838):200-1. No abstract available. PMID: 22817963
Psychedelic drugs have a rich and vibrant history as clinical aids for psychiatry. For two decades after the discovery of lysergide (LSD) in the 1940s, psychedelics were extensively studied and clinical progress was good. But research collapsed rapidly in 1966 when LSD was made illegal, and there was a subsequent hiatus of psychedelic research. After 40 years, this pause is now coming to an end, with many new studies and a refreshing approach to the research of psychedelic drugs. Lancet. 2012 Jul 21;380(9838):200-1. No abstract available. PMID: 22817963
Thursday, July 19, 2012
New Institute of Medicine Report Assessing PTSD Treatments at the DoD and the VA
Treatment for Posttraumatic Stress Disorder in Military and Veteran Populations: Initial Assessment (read free online)
As the U.S. reduces its military involvement in the Middle East, the Departments of Defense (DoD) and Veterans Affairs (VA) anticipate that increasing numbers of returning veterans will need PTSD services. As a result, Congress asked the DoD, in consultation with the VA, to sponsor an IOM study to assess both departments’ PTSD treatment programs and services. This first of two mandated reports examines some of the available programs to prevent, diagnose, treat, and rehabilitate those who have PTSD and encourages further research that can help to improve PTSD care.
(From page 257)
Many CAM (Complementary and Alternative Medicine) approaches are being used by people with PTSD as reported in the popular press, but these approaches are not necessarily being formally studied to assess their efficacy.
As the U.S. reduces its military involvement in the Middle East, the Departments of Defense (DoD) and Veterans Affairs (VA) anticipate that increasing numbers of returning veterans will need PTSD services. As a result, Congress asked the DoD, in consultation with the VA, to sponsor an IOM study to assess both departments’ PTSD treatment programs and services. This first of two mandated reports examines some of the available programs to prevent, diagnose, treat, and rehabilitate those who have PTSD and encourages further research that can help to improve PTSD care.
(From page 257)
Many CAM (Complementary and Alternative Medicine) approaches are being used by people with PTSD as reported in the popular press, but these approaches are not necessarily being formally studied to assess their efficacy.
Saturday, July 7, 2012
Be the witness: a mindfulness technique for tempering anger
'Self-distancing' can help people calm aggressive reactions, study finds
A new study reveals a simple strategy that people can use to minimize how angry and aggressive they get when they are provoked by others. MedicalXpress
A new study reveals a simple strategy that people can use to minimize how angry and aggressive they get when they are provoked by others. MedicalXpress
Sunday, July 1, 2012
Researcher urges British governments to facilitate, not hinder, research with psychedelics.
 |
| Dr. David Nutt |
Scientists should have access to illegal psychedelic drugs such as LSD and psilocybin to aid them in brain research, according to the government's former drug adviser Professor David Nutt. He said that research into the deepest mysteries of the brain, including consciousness and mental illness, had been curtailed by the prohibition of the drugs.
"Neuroscience should be trying to understand how the brain works," said Nutt, who is professor of neuropsychopharmacology at Imperial College London. "Psychedelics change the brain in, perhaps, the most profound way of any drug, at least in terms of understanding consciousness and connectivity. Therefore we should be doing a lot more of this research.
"Regulations, which are arbitrary, actually make it virtually impossible to research these drugs," said Nutt last month. "The effect these laws have had on research is greater than the effects that [George] Bush stopping stem cell research has had, because it's been going on since the 1960s." The Guardian
Saturday, June 23, 2012
Institute of Noetic Sciences interviews Johns Hopkins psilocybin researcher Roland Griffiths
 |
| Roland Griffiths and Cassandra
Vieten Download as mp3 |
Link to audio: "Psilocybin and quantum change in attitude and behavior"
The overall finding that psilocybin can occasion, in most people studied, mystical-type experiences having sustained personal meaning and spiritual significance, indicates that such experiences and the changes they produce are now amenable to rigorous prospective scientific study. Several ongoing studies are discussed, including a study of psilocybin on meditation and spiritual practice in healthy volunteers, a study of psilocybin in psychologically distressed cancer patients, and a study of psilocybin-facilitated treatment of drug cigarette smoking cessation. Noetic.org
Video presentation by Robin Carhart-Harris, lead author of fMRI study of effects of psilocybin on bloodflow in brain.
Lead author of 2012 British Journal of Psychiatry study (
Implications for psychedelic-assisted psychotherapy: a functional magnetic resonance imaging study with psilocybin.) discusses his work in video first presented at the Psychedelic Science in the 21st Century, a conference that took place in San Jose, California on April 15-18, 2010.
Monday, June 18, 2012
Poster Presentation From the International Research Congress on Integrative Medicine and Health 2012
P02.135. Measuring mindfulness: which aspects of mindfulness change following a brief telehealth intervention for PTSD (PDF)
The goal of this pilot study was to examine changes in self-reported levels of mindfulness in the context of an 8-week mindfulness telehealth intervention for military veterans with combat-related posttraumatic stress disorder (PTSD). Niles et al. BMC Complementary and Alternative Medicine 2012, 12(Suppl 1):P191
The goal of this pilot study was to examine changes in self-reported levels of mindfulness in the context of an 8-week mindfulness telehealth intervention for military veterans with combat-related posttraumatic stress disorder (PTSD). Niles et al. BMC Complementary and Alternative Medicine 2012, 12(Suppl 1):P191
DoD using yoga and meditation help them make better decisions on the battlefield and prevent trauma
For the past year, (Douglas C.) Johnson, a psychologist at the Naval Health Research Center’s Warfighter Performance Lab, in San Diego, has gathered blood and saliva samples from marines before and after they went through training, scanned their brains, recorded their heart rate and respiration, and given them cognitive and behavioral tests. Using this data, Johnson and his colleagues can adjust training to make troops more effective and limit the negative impacts of combat. Pacific Standard
PubMed search for articles on yoga/meditation in the military
Monday, June 11, 2012
Mindfulness-based psychological therapy helps reduce anxiety and depression in cancer patients
Mindfulness-based psychological therapy is rooted in Buddhist meditation techniques and includes the programmes mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT). Training and exercises in mindfulness teach the cancer patients to be more conscious of life as it happens instead of worrying about the past and the future. This may be thoughts about their past behaviour having contributed to their disease and fear of what will happen to them in future, including worries about death.
The findings have been published in the most prestigious international journal within clinical psychology research, Journal of Consulting and Clinical Psychology.
The findings have been published in the most prestigious international journal within clinical psychology research, Journal of Consulting and Clinical Psychology.
Saturday, June 9, 2012
New article from journal Behavior Modification: mindfulness, mantra, and compassion meditation as a treatment for PTSD
The Theoretical and Empirical Basis for Meditation as an Intervention for PTSD.
In spite of the existence of good empirically supported treatments for posttraumatic stress disorder (PTSD), consumers and providers continue to ask for more options for managing this common and often chronic condition. Meditation-based approaches are being widely implemented, but there is minimal research rigorously assessing their effectiveness. This article reviews meditation as an intervention for PTSD, considering three major types of meditative practices: mindfulness, mantra, and compassion meditation. The mechanisms by which these approaches may effectively reduce PTSD symptoms and improve quality of life are presented. Empirical evidence of the efficacy of meditation for PTSD is very limited but holds some promise. Additional evaluation of meditation-based treatment appears to be warranted.
Lang AJ, Strauss JL, Bomyea J, Bormann JE, Hickman SD, Good RC, Essex M.
Behav Modif. 2012 Nov;36(6):759-86. doi: 10.1177/0145445512441200. Epub 2012 Jun 5. Review.
PMID: 22669968
PDF
Cited by (Goggle Scholar)
In spite of the existence of good empirically supported treatments for posttraumatic stress disorder (PTSD), consumers and providers continue to ask for more options for managing this common and often chronic condition. Meditation-based approaches are being widely implemented, but there is minimal research rigorously assessing their effectiveness. This article reviews meditation as an intervention for PTSD, considering three major types of meditative practices: mindfulness, mantra, and compassion meditation. The mechanisms by which these approaches may effectively reduce PTSD symptoms and improve quality of life are presented. Empirical evidence of the efficacy of meditation for PTSD is very limited but holds some promise. Additional evaluation of meditation-based treatment appears to be warranted.
Lang AJ, Strauss JL, Bomyea J, Bormann JE, Hickman SD, Good RC, Essex M.
Behav Modif. 2012 Nov;36(6):759-86. doi: 10.1177/0145445512441200. Epub 2012 Jun 5. Review.
PMID: 22669968
Cited by (Goggle Scholar)
Professor starts class discussing clinical research on psychedelic drugs
Psychedelic studies
Watching his mother struggle with death stirred an interest for (Bruce) Sewick. As a result, he’s studied the clinical use of psychedelic drugs to treat the terminally ill for more than 15 years, and completed his master’s thesis on the topic in 1997.
“It’s all in memory of my mom,” he said.
Now, he’s hoping to pass that knowledge on to others by offering a summer course at College of DuPage called “Psychedelic Mindview” that will explore the role of psychedelic substances throughout history. Mysuburbanlife.com
Watching his mother struggle with death stirred an interest for (Bruce) Sewick. As a result, he’s studied the clinical use of psychedelic drugs to treat the terminally ill for more than 15 years, and completed his master’s thesis on the topic in 1997.
“It’s all in memory of my mom,” he said.
Now, he’s hoping to pass that knowledge on to others by offering a summer course at College of DuPage called “Psychedelic Mindview” that will explore the role of psychedelic substances throughout history. Mysuburbanlife.com
Tuesday, May 29, 2012
Prolonged exposure, mindfulness and emotion regulation
Prolonged Exposure, Mindfulness, and Emotion Regulation for the Treatment of PTSD
Although several studies have demonstrated the efficacy of prolonged exposure (PE) for the treatment of posttraumatic stress disorder (PTSD), there are concerns regarding its clinical applications. The exacerbation of symptoms during exposure, poor adherence to treatment, and early treatment dropout are suggested to occur because of an unwillingness for some PTSD clients to confront feared trauma-relevant stimuli and experience anxious arousal during exposure. The application of mindfulness and emotion regulation skills during PE may be a useful substitute for clients’ attempts to escape, avoid, or control anxious arousal during treatment. Lauren A. Frye, C. Richard Spates. Clinical Case Studies 1534650112446850, first published on May 24, 2012 as doi:10.1177/1534650112446850
Although several studies have demonstrated the efficacy of prolonged exposure (PE) for the treatment of posttraumatic stress disorder (PTSD), there are concerns regarding its clinical applications. The exacerbation of symptoms during exposure, poor adherence to treatment, and early treatment dropout are suggested to occur because of an unwillingness for some PTSD clients to confront feared trauma-relevant stimuli and experience anxious arousal during exposure. The application of mindfulness and emotion regulation skills during PE may be a useful substitute for clients’ attempts to escape, avoid, or control anxious arousal during treatment. Lauren A. Frye, C. Richard Spates. Clinical Case Studies 1534650112446850, first published on May 24, 2012 as doi:10.1177/1534650112446850
Monday, May 21, 2012
Psilocybin related PubMed articles published Jan to May 2012
1.
Psilocybin
Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward
Positive Relative to Negative Emotions Through Different Serotonergic
Subreceptors. Kometer
M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Biol
Psychiatry. 2012 May 9. [Epub ahead of print] PMID: 22578254
2.
High doses of
dextromethorphan, an NMDA antagonist, produce effects similar to classic
hallucinogens. Reissig
CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR.
Psychopharmacology
(Berl). 2012 Apr 13. [Epub ahead of print] PMID: 22526529
3.
Neuroimaging: a
scanner, colourfully. Roiser JP, Rees G. Curr Biol. 2012 Apr
10;22(7):R231-3. PMID: 22497939
4.
Prediction of psilocybin response in healthy
volunteers. Studerus
E, Gamma A, Kometer M, Vollenweider FX. PLoS One. 2012;7(2):e30800. Epub 2012
Feb 17. PMID: 22363492 Free PMC Article
5.
Hallucinogen
actions on human brain revealed. Lee HM, Roth BL. Proc Natl Acad Sci U S
A. 2012 Feb 7;109(6):1820-1. Epub 2012 Jan 30. No abstract available. PMID: 22308478
6.
Neural
correlates of the psychedelic state as determined by fMRI studies with psilocybin. Carhart-Harris
RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R,
Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ. Proc
Natl Acad Sci U S A. 2012 Feb 7;109(6):2138-43. Epub 2012 Jan 23. PMID: 22308440
7.
Implications for
psychedelic-assisted psychotherapy: functional magnetic resonance imaging study
with psilocybin. Carhart-Harris
RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, Hobden P, Sharp
DJ, Evans J, Feilding A, Wise RG, Nutt DJ. Br J Psychiatry. 2012
Mar;200(3):238-44. Epub 2012 Jan 26. PMID: 22282432
PubMed articles on PTSD and mindfulness (Limits: Humans and English, published past 12 months)
1.
Web-based post-traumatic stress disorder
education for military family members. Roy
MJ, Taylor P, Runge W, Grigsby E, Woolley M, Torgeson T. Mil Med. 2012 Mar;177(3):284-90.
PMID: 22479915
2.
Attention
bias toward threat is associated with exaggerated fear expression and impaired
extinction in PTSD.
Fani N, Tone EB, Phifer J, Norrholm SD,
Bradley B, Ressler KJ, Kamkwalala A, Jovanovic T. Psychol Med. 2012
Mar;42(3):533-43. Epub 2011 Aug 22.
PMID: 21854700
3.
Serious
psychological distress and diabetes: a review of the literature. Egede LE, Dismuke CE. Curr Psychiatry Rep.
2012 Feb;14(1):15-22. Review. PMID: 22002804
4.
Physical health
conditions associated with posttraumatic stress disorder in U.S. older adults:
results from wave 2 of the National Epidemiologic Survey on Alcohol and Related
Conditions.
Pietrzak RH, Goldstein RB, Southwick SM,
Grant BF. J Am Geriatr Soc. 2012 Feb;60(2):296-303. doi:
10.1111/j.1532-5415.2011.03788.x. Epub 2012 Jan 27. PMID: 22283516
5.
Comparison of
subjective cognitive complaints with neuropsychological tests in individuals
with mild vs more severe traumatic brain injuries. Jamora
CW, Young A, Ruff RM.
Brain Inj.
2012;26(1):36-47. PMID: 22149443
6.
The potential impact
of recruitment method on sample characteristics and treatment outcomes in a
psychosocial trial for women with co-occurring substance use disorder and PTSD. Winhusen T, Winstanley EL, Somoza E, Brigham
G. Drug Alcohol Depend. 2012 Jan 1;120(1-3):225-8. Epub 2011 Jul 12. PMID: 21752556
7.
The interactive
effects of emotional clarity and cognitive reappraisal in Posttraumatic Stress
Disorder.
Boden MT, Bonn-Miller MO, Kashdan TB,
Alvarez J, Gross JJ. J Anxiety Disord. 2012 Jan;26(1):233-8. Epub 2011 Nov 28. PMID:
22169054
8.
The effects of
dissociation on information processing for analogue trauma and neutral stimuli:
a laboratory study.
Olsen SA, Beck JG. J Anxiety Disord. 2012
Jan;26(1):225-32. Epub 2011 Nov 16. PMID: 22137464
9.
Association of
participation in a mindfulness
program with measures of PTSD, depression and quality of life in a veteran
sample.
Kearney DJ, McDermott K, Malte C,
Martinez M, Simpson TL. J Clin Psychol. 2012 Jan;68(1):101-16. doi:
10.1002/jclp.20853. Epub 2011 Nov 28. PMID: 22125187
10.
Peritraumatic
reactions and posttraumatic stress disorder symptoms after psychiatric
admission.
Ladois-Do
Pilar Rei A, Bui E, Bousquet B, Simon NM, Rieu J, Schmitt L, Billard J, Rodgers
R, Birmes P. J Nerv Ment Dis. 2012 Jan;200(1):88-90. PMID: 22210368
11.
Social cognition
impairments in relation to general cognitive deficits, injury severity, and
prefrontal lesions in traumatic brain injury patients. Spikman
JM, Timmerman ME, Milders MV, Veenstra WS, van der Naalt J. J Neurotrauma. 2012
Jan 1;29(1):101-11. Epub 2011 Nov 7.
PMID: 21933011
12.
The cognitive
neuroscience of true and false memories. Johnson MK, Raye CL, Mitchell KJ, Ankudowich
E. Nebr Symp Motiv. 2012;58:15-52. Review. PMID: 22303763
13.
Work-related
stress and posttraumatic stress in emergency medical services. Donnelly
E. Prehosp Emerg Care. 2012 Jan;16(1):76-85. PMID: 22128908
14.
Perceptual
processing advantages for trauma-related visual cues in post-traumatic stress disorder. Kleim B,
Ehring T, Ehlers A. Psychol Med. 2012 Jan;42(1):173-81. Epub 2011 Jun 21.
Articles in PubMed involving Psilocybin AND (PTSD OR cancer)
1.
Pilot study of
psilocybin treatment for anxiety in patients with advanced-stage cancer. Grob CS, Danforth AL, Chopra GS, Hagerty M,
McKay CR, Halberstadt AL, Greer GR. Arch Gen Psychiatry. 2011 Jan;68(1):71-8.
Epub 2010 Sep 6. PMID: 20819978. Citations (from Google Scholar)
PMID: 19780439.
3.
Psychedelic
drugs: the ups and downs of ecstasy. Check
E. Nature. 2004 May 13;429(6988):126-8. No abstract available. PMID: 15141183.
Act Nerv Super (Praha). 1975 Mar;17(1):29-30. No
abstract available. PMID: 1179966.
5.
EEG changes
after psilocybin in organic brain lesions. Kolarĩk J. Act Nerv Super (Praha). 1971;13(3):216-7. No abstract
available. PMID: 512214.
6.
Post-traumatic neurosis--theme
and variations.
Fellner CH. IMS Ind Med Surg. 1968
May;37(5):347-50. No abstract available. PMID: 5239850.
Thursday, May 17, 2012
New article on mindulness and PTSD from the Department of Neurology, Oregon Health & Science University
Conclusion: This study confirms in a clinical sample that mindful non-judging is
associated with PTSD symptoms and could represent a meaningful focus for
treatment.
Wahbeh H, Lu M, Oken B. Mindfulness (N Y). 2011 Dec 1;2(4):219-227. PMID: 22582091
Subscribe to:
Posts (Atom)